

Zeljko Reiner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4756874/zeljko-reiner-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

195
papers

44,994
citations

60
h-index

212
g-index

223
ext. papers

53,273
ext. citations

4.7
avg, IF

6.76
L-index

#	Paper	IF	Citations
195	Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. <i>Mediators of Inflammation</i> , 2022 , 2022, 8732360	4.3	4
194	Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review.. <i>Cardiovascular Therapeutics</i> , 2022 , 2022, 8129513	3.3	3
193	Prevalence of statin intolerance: a meta-analysis.. <i>European Heart Journal</i> , 2022 ,	9.5	8
192	The role of statins in lung cancer.. <i>Archives of Medical Science</i> , 2022 , 18, 141-152	2.9	1
191	Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 820260	5.4	6
190	Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. <i>Atherosclerosis</i> , 2022 , 348, 25-35	3.1	2
189	Prophylactic therapeutic plasma exchange in pregnant woman with Familial Chylomicronemia Syndrome - A case report.. <i>Transfusion and Apheresis Science</i> , 2021 , 103346	2.4	
188	Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
187	Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2021 , 166, 105499	10.2	20
186	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021 , 325, 99-109	3.1	22
185	Pregnancy in Familial Chylomicronemia Syndrome: Plasmapheresis as Therapeutic Approach. <i>Journal of the Endocrine Society</i> , 2021 , 5, A311-A311	0.4	78
184	The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 682352	5.4	2
183	In silico interactions of statins with cell death-inducing DNA fragmentation factor-like effector A (CIDEA). <i>Chemico-Biological Interactions</i> , 2021 , 345, 109528	5	1
182	Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection. <i>Frontiers in Pharmacology</i> , 2021 , 12, 575877	5.6	6
181	Fetal toxicity associated with statins: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2021 , 327, 59-67	3.1	6
180	Genistein as a regulator of signaling pathways and microRNAs in different types of cancers. <i>Cancer Cell International</i> , 2021 , 21, 388	6.4	8
179	Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9?. <i>Critical Reviews in Food Science and Nutrition</i> , 2021 , 61, 325-336	11.5	1

178	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 33-43	3.9	10
177	Peripheral arterial disease and intermittent claudication in coronary heart disease patients. <i>International Journal of Cardiology</i> , 2021 , 322, 227-232	3.2	5
176	Statin therapy and sex hormones. <i>European Journal of Pharmacology</i> , 2021 , 890, 173745	5.3	6
175	Effects of statins on preeclampsia: A systematic review. <i>Pregnancy Hypertension</i> , 2021 , 23, 123-130	2.6	7
174	Dietary supplements, vitamins and minerals as potential interventions against viruses: Perspectives for COVID-19. <i>International Journal for Vitamin and Nutrition Research</i> , 2021 , 1-18	1.7	16
173	Novel Experimental Agents for the Treatment of Hypercholesterolemia. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 91-100	3	8
172	Statin Therapy in Post-Operative Atrial Fibrillation: Focus on the Anti-Inflammatory Effects. <i>Journal of Cardiovascular Development and Disease</i> , 2021 , 8,	4.2	2
171	Resveratrol and cardiac fibrosis prevention and treatment. <i>Current Pharmaceutical Biotechnology</i> , 2021 ,	2.6	3
170	Postmarketing nutravigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. <i>Archives of Medical Science</i> , 2021 , 17, 856-863	2.9	7
169	Impact of Bariatric Surgery on Pulse Wave Velocity as a Measure of Arterial Stiffness: a Systematic Review and Meta-analysis. <i>Obesity Surgery</i> , 2021 , 31, 4461-4469	3.7	0
168	Quercetin as a Novel Therapeutic Approach for Lymphoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2021 , 2021, 3157867	6.7	4
167	The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Mediators of Inflammation</i> , 2021 , 2021, 9661752	4.3	1
166	The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis. <i>Current Medicinal Chemistry</i> , 2021 , 28, 6066-6081	4.3	4
165	The Effect of Bariatric Surgery on Circulating Levels of Oxidized Low-Density Lipoproteins Is Apparently Independent of Changes in Body Mass Index: A Systematic Review and Meta-Analysis.. <i>Oxidative Medicine and Cellular Longevity</i> , 2021 , 2021, 4136071	6.7	0
164	Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer. <i>Cancer Cell International</i> , 2020 , 20, 560	6.4	11
163	Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. <i>Pharmacological Research</i> , 2020 , 158, 104891	10.2	42
162	Statins and the COVID-19 main protease: evidence on direct interaction. <i>Archives of Medical Science</i> , 2020 , 16, 490-496	2.9	164
161	The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Nutrition ESPEN</i> , 2020 , 38, 43-49	1.3	8

160	The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. <i>Lipids in Health and Disease</i> , 2020 , 19, 112	4.4	11
159	The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair. <i>Heart Failure Reviews</i> , 2020 , 1	5	0
158	The effects of omega-3 fatty acids supplementation on metabolic status in pregnant women: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020 , 19, 1685-1699	2.5	2
157	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , 2020 , 33, 155-179	7	20
156	Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 45, 102381	4	3
155	At a glance: economic impact of industry-sponsored clinical trials of pharmaceutical products. <i>Journal of Medical Economics</i> , 2020 , 23, 1193-1195	2.4	0
154	Molecular and Biological Functions of Quercetin as a Natural Solution for Cardiovascular Disease Prevention and Treatment. <i>Plant Foods for Human Nutrition</i> , 2020 , 75, 307-315	3.9	9
153	Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020 , 155, 104719	10.2	7
152	Effect of green cardamom on lipoproteins, glycemic control and anthropometric parameters: A meta-analysis of randomized clinical trials. <i>Clinical Nutrition ESPEN</i> , 2020 , 37, 24-33	1.3	2
151	The Effects of N-acetylcysteine on Inflammatory Markers and Homocysteine: A Systematic Review and Meta-analysis of Randomized Controlled Trials 2020 , 26, 214-224		
150	Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. <i>European Journal of Preventive Cardiology</i> , 2020 ,	3.9	4
149	Effects of resistant starch on glycemic control, serum lipoproteins and systemic inflammation in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled clinical trials. <i>Critical Reviews in Food Science and Nutrition</i> , 2020 , 60, 3172-3184	11.5	18
148	The effects of -3 fatty acids from flaxseed oil on genetic and metabolic profiles in patients with gestational diabetes mellitus: a randomised, double-blind, placebo-controlled trial. <i>British Journal of Nutrition</i> , 2020 , 123, 792-799	3.6	17
147	The effects of grape seed extract on glycemic control, serum lipoproteins, inflammation, and body weight: A systematic review and meta-analysis of randomized controlled trials. <i>Phytotherapy Research</i> , 2020 , 34, 239-253	6.7	15
146	The effects of saffron (<i>Crocus sativus</i> L.) on mental health parameters and C-reactive protein: A meta-analysis of randomized clinical trials. <i>Complementary Therapies in Medicine</i> , 2020 , 48, 102250	3.5	11
145	Medicinal plants and bioactive natural compounds as inhibitors of HMG-CoA reductase: A literature review. <i>BioFactors</i> , 2020 , 46, 906-926	6.1	11
144	The Therapeutic Potential of Anthocyanins: Current Approaches Based on Their Molecular Mechanism of Action. <i>Frontiers in Pharmacology</i> , 2020 , 11, 1300	5.6	55
143	Inflammatory Biomarkers for Cardiovascular Risk Stratification in Familial Hypercholesterolemia. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020 , 177, 25-52	2.9	4

142	A systematic review and meta-analysis: The effects of probiotic supplementation on metabolic profile in patients with neurological disorders. <i>Complementary Therapies in Medicine</i> , 2020 , 53, 102507	3.5	7
141	The effects of L-carnitine supplementation on indicators of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020 , 19, 1879-1894	2.5	9
140	The effects of catechin on endothelial function: A systematic review and meta-analysis of randomized controlled trials. <i>Critical Reviews in Food Science and Nutrition</i> , 2020 , 60, 2369-2378	11.5	3
139	Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1630-1636	3.9	11
138	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020 , 41, 111-188	9.5	2236
137	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320908698	3.9	25
136	The Therapeutic Potential of Nanoparticles to Reduce Inflammation in Atherosclerosis. <i>Biomolecules</i> , 2019 , 9,	5.9	13
135	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , 2019 , 39, e1-e8	1.7	18
134	The Role of Mesenchymal Stem Cells in Atherosclerosis: Prospects for Therapy via the Modulation of Inflammatory Milieu. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	10
133	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. <i>Cardiovascular Diabetology</i> , 2019 , 18, 71	8.7	64
132	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , 2019 , 285, 135-146	3.1	106
131	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019 , 143, 1-16	10.2	54
130	Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?. <i>Current Atherosclerosis Reports</i> , 2019 , 21, 14	6	11
129	A review of gene- and cell-based therapies for familial hypercholesterolemia. <i>Pharmacological Research</i> , 2019 , 143, 119-132	10.2	18
128	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 824-835	3.9	288
127	The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. <i>Food and Function</i> , 2019 , 10, 6042-6051	6.1	65
126	The effects of spirulina on glycemic control and serum lipoproteins in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. <i>Phytotherapy Research</i> , 2019 , 33, 2609-2621	6.7	13
125	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019 , 140, 2054-2062	16.7	41

124	Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3
123	The effects of L-carnitine supplementation on glycemic control: a systematic review and meta-analysis of randomized controlled trials. <i>EXCLI Journal</i> , 2019 , 18, 631-643	2.4	4
122	Macrophage: A Key Therapeutic Target in Atherosclerosis?. <i>Current Pharmaceutical Design</i> , 2019 , 25, 3165-3174	3.3	13
121	The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Current Pharmaceutical Design</i> , 2019 , 25, 3266-3281	3.3	3
120	Pulse wave velocity as a measure of arterial stiffness in patients with familial hypercholesterolemia: a systematic review and meta-analysis. <i>Archives of Medical Science</i> , 2019 , 15, 1365-1374 ¹⁰	2.9	10
119	Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry. <i>Journal of Hypertension</i> , 2019 , 37, 2015-2023	1.9	3
118	The year in cardiology 2018: prevention. <i>European Heart Journal</i> , 2019 , 40, 336-344	9.5	14
117	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. <i>European Journal of Epidemiology</i> , 2019 , 34, 247-258	12.1	15
116	Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. <i>BMJ Open</i> , 2019 , 8, e021508	3	10
115	Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 801-809	4.9	15
114	Improvement of endothelial function by pitavastatin: a meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 279-286	4	21
113	PCSK9 and infection: A potentially useful or dangerous association?. <i>Journal of Cellular Physiology</i> , 2018 , 233, 2920-2927	7	21
112	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. <i>International Journal of Cardiology</i> , 2018 , 272, 20-25	3.2	19
111	Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Medicine</i> , 2018 , 50, 565-575	1.5	29
110	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". <i>Atherosclerosis</i> , 2018 , 275, 265-272	3.1	69
109	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. <i>Korean Circulation Journal</i> , 2018 , 48, 1097-1119	2.2	10
108	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018 , 277, 234-255	3.1	93
107	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. <i>Data in Brief</i> , 2018 , 21, 1334-1336	1.2	3

106	The Role of Nutraceuticals in Statin Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 96-118	15.1	157
105	Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 197-208	3.9	16
104	Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. <i>Complementary Therapies in Medicine</i> , 2017 , 33, 1-5	3.5	88
103	Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. <i>Pharmacological Research</i> , 2017 , 122, 53-65	10.2	49
102	Hypertriglyceridaemia and risk of coronary artery disease. <i>Nature Reviews Cardiology</i> , 2017 , 14, 401-411	14.8	178
101	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017 , 75, 731-767	6.4	186
100	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017 , 13, 965-1005	2.9	173
99	Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1383-1401	3.9	32
98	Statistical vs clinical significance: A matter of debate for orlistat treatment. <i>Pharmacological Research</i> , 2017 , 124, 158-159	10.2	
97	Regular exercise behaviour and intention and symptoms of anxiety and depression in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 84-91	3.9	14
96	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016 , 37, 2999-3058	17.81	
95	Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. <i>European Journal of Preventive Cardiology</i> , 2017 , 23, 2007-2018	3.9	96
94	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 162-71	7	24
93	Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. <i>Drugs</i> , 2016 , 76, 947-56	12.1	38
92	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 636-48	3.9	549
91	Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey. <i>Atherosclerosis</i> , 2016 , 246, 243-50	3.1	121
90	Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016 , 212, 160-8	3.2	39
89	The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. <i>International Journal of Cardiology</i> , 2016 , 209, 284-90	3.2	57

88	Educational level and risk profile and risk control in patients with coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 881-90	3.9	20
87	A Systematic Review and Meta-Analysis of Controlled Trials on the Effects of Statin and Fibrate Therapies on Plasma Homocysteine Levels. <i>Current Medicinal Chemistry</i> , 2016 , 23, 4490-4503	4.3	15
86	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016 , 22, 1-32	1.7	60
85	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016 , 18, C2-C12	1.5	56
84	Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 1618-27	3.9	10
83	Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 1202-10	3.9	32
82	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>Atherosclerosis</i> , 2016 , 253, 281-344	3.1	519
81	Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Metabolism: Clinical and Experimental</i> , 2016 , 65, 1664-1678	12.7	45
80	Management of patients with familial hypercholesterolaemia. <i>Nature Reviews Cardiology</i> , 2015 , 12, 565-578	7.8	79
79	Cardiovascular disease (CVD) risk factors in older adults - Perception and reality. <i>Archives of Gerontology and Geriatrics</i> , 2015 , 61, 88-92	4	15
78	Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 1354-62	3.9	60
77	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015 , 19, 1-12	1.7	50
76	A comparison of European and US guidelines for familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2015 , 26, 215-20	4.4	10
75	Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. <i>Atherosclerosis</i> , 2015 , 241, 169-75	3.1	114
74	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015 , 14, 133	8.7	74
73	Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 1212-9	3.9	28
72	Adverse effects of statins - myths and reality. <i>Current Pharmaceutical Design</i> , 2015 , 21, 1220-6	3.3	78
71	Similarities and differences between European and United States guidelines for the management of dyslipidaemias. <i>Kardiologia Polska</i> , 2015 , 73, 471-7	0.9	3

70	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , 2014 , 35, 960-8	9.5	222
69	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 136.e1-136.e56	1.5	8
68	Passive smoking and smoking cessation among patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. <i>European Heart Journal</i> , 2014 , 35, 590-8	9.5	36
67	Primary prevention of cardiovascular disease with statins in the elderly. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 420	6	20
66	Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction. <i>Atherosclerosis</i> , 2014 , 235, 21-30	3.1	181
65	Resistance and intolerance to statins. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014 , 24, 1057-66	6.5	132
64	Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. <i>Circulation</i> , 2014 , 129, 999-1008	16.7	153
63	Statins in the primary prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2013 , 10, 453-64	14.8	119
62	Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013 , 23, 799-807	4.5	85
61	Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. <i>Atherosclerosis</i> , 2013 , 231, 300-7	3.1	49
60	Polypill is not a vaccine-like solution for primary cardiovascular disease prevention in all parts of the world. <i>Journal of Epidemiology and Community Health</i> , 2013 , 67, 981-2	5.1	3
59	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2013 , 34, 2995-327	9.5	1444
58	Recomendações Europeias para a prevenção da doença cardiovascular na prática clínica (versão de 2012). <i>Revista Portuguesa De Cardiologia</i> , 2013 , 32, 553.e1-553.e77	1	4
57	Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 53.e1-53.e46	1.5	17
56	Mutation detection in Croatian patients with familial hypercholesterolemia. <i>Annals of Human Genetics</i> , 2013 , 77, 22-30	2.2	11
55	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2013 , 34, 2159-219	9.5	3400
54	Prevalence and types of persistent dyslipidemia in patients treated with statins. <i>Croatian Medical Journal</i> , 2013 , 54, 339-45	1.6	25
53	Population-level changes to promote cardiovascular health. <i>European Journal of Preventive Cardiology</i> , 2013 , 20, 409-21	3.9	76

52	Statins for primary prevention: problems with cardiovascular-risk estimation?. <i>Nature Reviews Cardiology</i> , 2013 , 10, 547	14.8	3
51	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). <i>European Heart Journal</i> , 2012 , 33, 1635-701	3.1	286
50	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). <i>European Heart Journal</i> , 2012 , 33, 1635-701	9.5	2797
49	Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , 2012 , 33, 2451-96	9.5	2866
48	Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. <i>European Heart Journal</i> , 2012 , 33, 2865-72	9.5	41
47	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2012 , 14, 803-69	12.3	1892
46	Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques. <i>Fundamental and Clinical Pharmacology</i> , 2012 , 26, 163-74	3.1	24
45	Third universal definition of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1581-98	15.1	2143
44	Dyslipidemias in the prevention of cardiovascular disease: risks and causality. <i>Current Cardiology Reports</i> , 2012 , 14, 709-20	4.2	71
43	European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). <i>International Journal of Behavioral Medicine</i> , 2012 , 19, 403-68	2.6	196
42	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , 2012 , 65, 938.e1-938.e59	1.5	27
41	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2012 , 33, 2719-47	9.5	2638
40	The perception and knowledge of cardiovascular risk factors among medical students. <i>Croatian Medical Journal</i> , 2012 , 53, 278-84	1.6	23
39	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012 , 33, 1767-847	9.5	3691
38	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012 , 33, 2569-619	9.5	3978
37	A pilot Croatian survey of risk factor (CRO-SURF) management in patients with cardiovascular disease. <i>Collegium Antropologicum</i> , 2012 , 36, 369-73	0.1	1
36	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011 , 32, 1769-818	9.5	2020
35	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011 , 32, 2851-906	9.5	1126

34	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>Atherosclerosis</i> , 2011 , 217 Suppl 1, S1-44	3.1	152
33	ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>Atherosclerosis</i> , 2011 , 217, 3-46	3.1	459
32	Impact of Treating Dyslipidemia on Cardiovascular Events 2011 , 238-246		1
31	Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. <i>Journal of Hypertension</i> , 2011 , 29, 1641-8	1.9	74
30	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011 , 32, 1345-61	9.5	793
29	Diabetic dyslipidemia or Qdiabetes lipidusQ. <i>Expert Review of Cardiovascular Therapy</i> , 2011 , 9, 341-8	2.5	9
28	Continental-Mediterranean and rural-urban differences in cardiovascular risk factors in Croatian population. <i>Croatian Medical Journal</i> , 2011 , 52, 566-75	1.6	21
27	Combined therapy in the treatment of dyslipidemia. <i>Fundamental and Clinical Pharmacology</i> , 2010 , 24, 19-28	3.1	70
26	Management of overweight and obese patients with coronary heart disease across Europe. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010 , 17, 447-54		27
25	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010 , 31, 2844-53	9.5	1100
24	EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010 , 17, 530-40		155
23	PhysiciansQperception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. <i>Atherosclerosis</i> , 2010 , 213, 598-603	3.1	93
22	Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. <i>Preventive Medicine</i> , 2010 , 51, 494-6	4.3	43
21	Combination therapy with prescription omega-3-acid ethyl esters and statin improves non-HDL-C more effectively than statin alone. <i>Clinical Lipidology</i> , 2010 , 5, 325-328		1
20	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. <i>American Journal of Cardiology</i> , 2008 , 102, 1K-34K	3	98
19	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , 2008 , 102, 1K-34K	3	280
18	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. <i>Diabetes and Vascular Disease Research</i> , 2008 , 5, 319-35	3.3	192
17	Differences in risk factors for coronary heart disease in patients from continental and Mediterranean regions of Croatia. <i>Wiener Klinische Wochenschrift</i> , 2008 , 120, 684-92	2.3	13

16	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). <i>European Heart Journal</i> , 2007 , 28, 2375-414	9.5	1029
15	The burden of hyperlipidaemia and diabetes in cardiovascular diseases. <i>Fundamental and Clinical Pharmacology</i> , 2007 , 21 Suppl 2, 1-3	3.1	26
14	Clinical study on the effect of simvastatin on paraoxonase activity. <i>Arzneimittelforschung</i> , 2007 , 57, 647-53		11
13	European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007 , 14 Suppl 2, S1-S113		751
12	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. <i>Atherosclerosis</i> , 2007 , 194, 1-45	3.1	190
11	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i>		309
10	Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data. <i>Psychiatria Danubina</i> , 2007 , 19, 270-81	1.8	12
9	Rice policosanol does not have any effects on blood coagulation factors in hypercholesterolemic patients. <i>Collegium Antropologicum</i> , 2007 , 31, 1061-4	0.1	4
8	Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2006 , 13, 646-54		28
7	Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients. <i>Clinical Drug Investigation</i> , 2005 , 25, 701-7	3.2	37
6	Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. <i>American Journal of Cardiology</i> , 2005 , 96, 1107-9	3	110
5	Clinical Study on the Effect of Simvastatin on Butyrylcholinesterase Activity. <i>Arzneimittelforschung</i> , 2005 , 55, 271-275		1
4	Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service. <i>Croatian Medical Journal</i> , 2005 , 46, 984-9	1.6	9
3	Atherosclerosis of retinal arteries in men: role of serum lipoproteins and apoproteins. <i>Croatian Medical Journal</i> , 2004 , 45, 333-7	1.6	11
2	Oxidative stress mediated cytogenotoxicological effects of phytol in wistar albino rats. <i>Advances in Traditional Medicine</i> ,1	1.4	
1	Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> ,	10.3	3